MAC Lung Disease Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts

DelveInsight's "MAC Lung Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the MAC Lung Disease, historical and forecasted epidemiology as well as the MAC Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of MAC Lung Disease, offering comprehensive insights into the MAC Lung Disease revenue trends, prevalence, and treatment landscape. The report delves into key MAC Lung Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging MAC Lung Disease therapies. Additionally, we cover the landscape of MAC Lung Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of MAC Lung Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the MAC Lung Disease space.

To Know in detail about the MAC Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; MAC Lung Disease Market Forecast
https://www.delveinsight.com/sample-request/mac-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the MAC Lung Disease Market Report:
• The MAC Lung Disease market size was valued ~USD 474 million in 2023 and is anticipated to grow with a significant CAGR of 14.2% during the study period (2020-2034)
• In February 2025, AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapeutics from its boron chemistry platform, has submitted an amended statistical analysis plan to the FDA. The amendment designates the Quality of Life - Bronchiectasis (QOL-B) respiratory domain patient-reported outcome (PRO) instrument as the primary efficacy endpoint for the Phase 3 segment of the EBO-301 trial. The company aims to assess whether the Phase 3 results align with the Phase 2 findings, which indicated potential clinical proof-of-concept. AN2 plans to review the outcomes of both phases with the FDA to explore potential registrational pathways
• In 2023, the market for MAC lung disease in the United States was valued at around USD 343.6 million, with expectations of growth driven by the introduction of new and emerging therapies
• In 2023, the combined market size of the EU4 and the UK was estimated at approximately USD 18.5 million, accounting for nearly 3.9% of the total market revenue across the 7MM.
• In 2023, Germany dominated the market among the EU4 countries and the UK, with an estimated revenue of approximately USD 5.2 million, while France and Italy each contributed around USD 4.3 million.
• In 2023, Japan's MAC lung disease market was valued at approximately USD 111.8 million and is expected to grow throughout the forecast period (2024-2034).
• Projections suggest that MNKD-101 is expected to generate approximately USD 477.7 million across the 7MM by 2034.
• MNKD-101, a nebulized clofazimine formulation, is currently in Phase III clinical trials and is anticipated to enter the market by 2027.
• Key MAC Lung Disease Companies: Insmed, Mannkind Corporation, Johnson and Johnson (Janssen Pharmaceutical K.K.), Spero Therapeutics, AN2 Therapeutics, Inc, and others
• Key MAC Lung Disease Therapies: ARIKAYCE (Amikacin Liposome Inhalation Suspension), MNKD-101 (clofazimine inhalation suspension), Bedaquiline fumarate (TMC207), SPR720 (fobrepodacin), Epetraborole, RHB-204, and others
• DelveInsight's estimates for 2023 indicate that there were around 119,000 diagnosed prevalent cases of Mycobacterium avium Complex (MAC) lung disease across the 7MM. The United States accounted for approximately 64% of these cases, while the EU4 and the UK collectively contributed nearly 8%, and Japan represented 28% of the total cases.
• The MAC Lung Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage MAC Lung Disease pipeline products will significantly revolutionize the MAC Lung Disease market dynamics.
• In 2023, the estimated number of diagnosed prevalent cases of NTM lung disease across the 7MM was approximately 151,000, with projections indicating an increase by 2034.
• In 2023, the United States recorded around 40,000 diagnosed prevalent cases of NTM lung disease in males and approximately 55,000 cases in females.
• In 2023, across the 7MM, the species-specific prevalent cases of NTM lung disease were estimated at approximately 119,000 for MAC, 6,000 for Mycobacterium abscessus, and 27,000 for other species.
• In 2023, the United States recorded the highest number of diagnosed prevalent cases of MAC lung disease among the 7MM, totaling around 76,000 cases. This number is expected to rise by 2034.
• In 2023, Germany reported the highest number of diagnosed prevalent cases of MAC lung disease among the EU4 and the UK, with around 2,600 cases, followed by Italy with approximately 2,200 cases. Conversely, Spain had the lowest count, with about 700 cases.
• In 2023, Japan recorded around 33,000 diagnosed prevalent cases of MAC lung disease, with projections indicating potential changes by 2034.

MAC Lung Disease Overview
MAC Lung Disease (Mycobacterium Avium Complex Lung Disease) is a chronic bacterial infection caused by Mycobacterium avium complex (MAC), a group of nontuberculous mycobacteria (NTM). It primarily affects the lungs, leading to symptoms such as persistent cough, fatigue, shortness of breath, weight loss, and fever. MAC lung disease is more common in individuals with weakened immune systems or underlying lung conditions like chronic obstructive pulmonary disease (COPD) or bronchiectasis. Diagnosis involves sputum cultures, chest imaging, and clinical evaluation, while treatment typically includes prolonged antibiotic therapy to manage the infection and prevent disease progression.

Get a Free sample for the MAC Lung Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/mac-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

MAC Lung Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

MAC Lung Disease Epidemiology Segmentation:
The MAC Lung Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of MAC Lung Disease
• Prevalent Cases of MAC Lung Disease by severity
• Gender-specific Prevalence of MAC Lung Disease
• Diagnosed Cases of Episodic and Chronic MAC Lung Disease

Download the report to understand which factors are driving MAC Lung Disease epidemiology trends @ MAC Lung Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/mac-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

MAC Lung Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the MAC Lung Disease market or expected to get launched during the study period. The analysis covers MAC Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the MAC Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

MAC Lung Disease Therapies and Key Companies
• ARIKAYCE (Amikacin Liposome Inhalation Suspension): Insmed
• MNKD-101 (clofazimine inhalation suspension): Mannkind Corporation
• Bedaquiline fumarate (TMC207): Johnson and Johnson (Janssen Pharmaceutical K.K.)
• SPR720 (fobrepodacin): Spero Therapeutics
• Epetraborole: AN2 Therapeutics, Inc
• RHB-204: RedHill Biopharma Limited

Discover more about therapies set to grab major MAC Lung Disease market share @ MAC Lung Disease Treatment Landscape
https://www.delveinsight.com/sample-request/mac-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

MAC Lung Disease Market Drivers
• Rising Disease Prevalence
• Advancements in Treatment
• Improved Diagnostic Techniques
• Growing Awareness
• Regulatory Support

MAC Lung Disease Market Barriers
• Limited Treatment Options
• Antibiotic Resistance
• High Treatment Costs
• Delayed Diagnosis
• Side Effects of Therapies

Scope of the MAC Lung Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key MAC Lung Disease Companies: Insmed, Mannkind Corporation, Johnson and Johnson (Janssen Pharmaceutical K.K.), Spero Therapeutics, AN2 Therapeutics, Inc, and others
• Key MAC Lung Disease Therapies: ARIKAYCE (Amikacin Liposome Inhalation Suspension), MNKD-101 (clofazimine inhalation suspension), Bedaquiline fumarate (TMC207), SPR720 (fobrepodacin), Epetraborole, RHB-204, and others
• MAC Lung Disease Therapeutic Assessment: MAC Lung Disease current marketed and MAC Lung Disease emerging therapies
• MAC Lung Disease Market Dynamics: MAC Lung Disease market drivers and MAC Lung Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• MAC Lung Disease Unmet Needs, KOL's views, Analyst's views, MAC Lung Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.